HCM
CLVS

Hayman Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Hayman Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100,000
Closed -$1.92M – 4
2016
Q1 		$1.92M Buy
+100,000
New +$2.12M 4.31% 3

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hayman Capital Management's CLVS Position: Q2 2016 in Review

Hayman Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2016, closing a stake of 100,000 shares — an estimated $1.92M sold.

Hayman Capital Management first reported a position in CLVS in Q1 2016 and held it in 1 quarter. The position peaked at $1.92M in Q1 2016. 122 funds tracked by Wall St. Rank hold CLVS as of Q2 2016.

  • Hayman Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2016 after selling out during the quarter.
  • Hayman Capital Management sold 100,000 Clovis Oncology, Inc. shares in Q2 2016, an estimated $1.92M.
  • Hayman Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 1 quarter.
  • Hayman Capital Management's Clovis Oncology, Inc. position peaked at $1.92M in Q1 2016.
  • 122 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2016.

Based on Hayman Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.